{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:56:51Z","timestamp":1785787011861,"version":"3.56.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02397-x","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:26:39Z","timestamp":1785738399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence"],"prefix":"10.1007","volume":"28","author":[{"given":"Daniel","family":"Akrawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh D.","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Malcolm","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"3","key":"2397_CR1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00277-024-06143-7","volume":"104","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Gay F, Landgren O, Mateos MV, Moreau P, Touzeau C, et al. Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies. Ann Hematol. 2025;104(3):1329\u201351. https:\/\/doi.org\/10.1007\/s00277-024-06143-7.","journal-title":"Ann Hematol"},{"issue":"3","key":"2397_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030354","volume":"17","author":"F Fazio","year":"2025","unstructured":"Fazio F, Gherardini M, Rossi E, Za T, Di Landro F, Mor\u00e8 S, et al. Long-term survival with multiple myeloma: an Italian experience. Cancers (Basel). 2025;17(3):354. https:\/\/doi.org\/10.3390\/cancers17030354.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2397_CR3","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/cir.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7\u201322. https:\/\/doi.org\/10.1161\/cir.0000000000000792.","journal-title":"Circulation"},{"issue":"4","key":"2397_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000442511","volume":"1","author":"P Yadav","year":"2016","unstructured":"Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel). 2016;1(4):241\u201357. https:\/\/doi.org\/10.1159\/000442511.","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"2397_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333. https:\/\/doi.org\/10.4065\/78.1.21.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"2397_CR6","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/jth.12724","volume":"12","author":"M Hultcrantz","year":"2014","unstructured":"Hultcrantz M, Pfeiffer RM, Bj\u00f6rkholm M, Goldin LR, Turesson I, Schulman S, et al. Elevated risk of venous but not arterial thrombosis in Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma. J Thromb Haemost. 2014;12(11):1816\u201321. https:\/\/doi.org\/10.1111\/jth.12724.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2397_CR7","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4519.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2397_CR8","doi-asserted-by":"publisher","first-page":"e12210","DOI":"10.1002\/pul2.12210","volume":"13","author":"V Maddipati","year":"2023","unstructured":"Maddipati V, Sankhyan P, Goswami DP, Mahajan A. Pulmonary hypertension in patients with multiple myeloma: A comprehensive review. Pulm Circ. 2023;13(2):e12210. https:\/\/doi.org\/10.1002\/pul2.12210.","journal-title":"Pulm Circ"},{"issue":"1","key":"2397_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/ejh.12677","volume":"97","author":"S Danhof","year":"2016","unstructured":"Danhof S, Schreder M, Rasche L, Strifler S, Einsele H, Knop S. Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors. Eur J Haematol. 2016;97(1):25\u201332. https:\/\/doi.org\/10.1111\/ejh.12677.","journal-title":"Eur J Haematol"},{"issue":"1","key":"2397_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, et al. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5(1):1\u201321. https:\/\/doi.org\/10.1016\/j.jaccao.2022.12.005.","journal-title":"JACC CardioOncol"},{"key":"2397_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2147\/dddt.S159818","volume":"12","author":"F Zhao","year":"2018","unstructured":"Zhao F, Yang B, Wang J, Zhang R, Liu J, Yin F, et al. Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib. Drug Des Devel Ther. 2018;12:1525\u201331. https:\/\/doi.org\/10.2147\/dddt.S159818.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"2397_CR12","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1159\/000520382","volume":"14","author":"Y Alali","year":"2021","unstructured":"Alali Y, Baljevic M. Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report. Case Rep Oncol. 2021;14(3):1853\u20139. https:\/\/doi.org\/10.1159\/000520382.","journal-title":"Case Rep Oncol"},{"issue":"4","key":"2397_CR13","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/01480545.2020.1835945","volume":"45","author":"Y Ling","year":"2022","unstructured":"Ling Y, Li R, Zhong J, Zhao Y, Chen Z. Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis. Drug Chem Toxicol. 2022;45(4):1443\u20138. https:\/\/doi.org\/10.1080\/01480545.2020.1835945.","journal-title":"Drug Chem Toxicol"},{"issue":"2","key":"2397_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/bcp.15499","volume":"89","author":"Z Al-Yafeai","year":"2023","unstructured":"Al-Yafeai Z, Ghoweba M, Ananthaneni A, Abduljabar H, Aziz D. Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study. Br J Clin Pharmacol. 2023;89(2):641\u20138. https:\/\/doi.org\/10.1111\/bcp.15499.","journal-title":"Br J Clin Pharmacol"},{"key":"2397_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400101","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Shan C, Zhang X, Liu Y, Xia Y, Wang Y. Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study. Front Immunol. 2024;15:1400101. https:\/\/doi.org\/10.3389\/fimmu.2024.1400101.","journal-title":"Front Immunol"},{"issue":"20","key":"2397_CR16","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1002\/cncr.31680","volume":"124","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124(20):4032\u201343. https:\/\/doi.org\/10.1002\/cncr.31680.","journal-title":"Cancer"},{"issue":"15","key":"2397_CR17","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1158\/1078-0432.Ccr-06-0511","volume":"12","author":"F Giles","year":"2006","unstructured":"Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12(15):4628\u201335. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-0511.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2397_CR18","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","volume":"46","author":"N Uaprasert","year":"2010","unstructured":"Uaprasert N, Voorhees PM, Mackman N, Key NS. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer. 2010;46(10):1790\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2010.03.007.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2397_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/jco.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21(1):16\u20139. https:\/\/doi.org\/10.1200\/jco.2003.03.139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2397_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29\u201337. https:\/\/doi.org\/10.1016\/s1470-2045(09)70284-0.","journal-title":"Lancet Oncol"},{"key":"2397_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104040","volume":"187","author":"BA Costa","year":"2023","unstructured":"Costa BA, Mouhieddine TH, Ortiz RJ, Richter J. Revisiting the role of alkylating agents in multiple myeloma: up-to-date evidence and future perspectives. Crit Rev Oncol Hematol. 2023;187:104040. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104040.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"2397_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/leu.2013.293","volume":"28","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981\u201392. https:\/\/doi.org\/10.1038\/leu.2013.293.","journal-title":"Leukemia"},{"issue":"6","key":"2397_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/clc.20904","volume":"34","author":"V Feliz","year":"2011","unstructured":"Feliz V, Saiyad S, Ramarao SM, Khan H, Leonelli F, Guglin M. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol. 2011;34(6):356\u20139. https:\/\/doi.org\/10.1002\/clc.20904.","journal-title":"Clin Cardiol"},{"issue":"5","key":"2397_CR24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024;6(5):655\u201377. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.016.","journal-title":"JACC CardioOncol"},{"issue":"9","key":"2397_CR25","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324. https:\/\/doi.org\/10.1002\/ajh.27422.","journal-title":"Am J Hematol"},{"issue":"24","key":"2397_CR26","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"issue":"6","key":"2397_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"issue":"11","key":"2397_CR28","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2213614.","journal-title":"N Engl J Med"},{"issue":"4","key":"2397_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"issue":"10","key":"2397_CR30","doi-asserted-by":"publisher","first-page":"e2437222","DOI":"10.1001\/jamanetworkopen.2024.37222","volume":"7","author":"D Koeckerling","year":"2024","unstructured":"Koeckerling D, Reddy RK, Barker J, Eichhorn C, Divall P, Howard JP, et al. Cardiovascular events after chimeric antigen receptor T-cell therapy for advanced hematologic malignant neoplasms: a meta-analysis. JAMA Netw Open. 2024;7(10):e2437222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37222.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2397_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40959-024-00252-y","volume":"10","author":"S Maleki","year":"2024","unstructured":"Maleki S, Esmaeili Z, Seighali N, Shafiee A, Namin SM, Zavareh MAT, et al. Cardiac adverse events after Chimeric Antigen Receptor (CAR) T cell therapies: an updated systematic review and meta-analysis. Cardiooncology. 2024;10(1):52. https:\/\/doi.org\/10.1186\/s40959-024-00252-y.","journal-title":"Cardiooncology"},{"issue":"4","key":"2397_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","volume":"9","author":"R Al Hamed","year":"2019","unstructured":"Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9(4):44. https:\/\/doi.org\/10.1038\/s41408-019-0205-9.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2397_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00905-8","volume":"13","author":"J C\u00f4t\u00e9","year":"2023","unstructured":"C\u00f4t\u00e9 J, LeBlanc R, Mian H, Chu MP, McCurdy A, Masih-Khan E, et al. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer J. 2023;13(1):137. https:\/\/doi.org\/10.1038\/s41408-023-00905-8.","journal-title":"Blood Cancer J"},{"issue":"4","key":"2397_CR34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jaccao.2024.06.004","volume":"6","author":"DG Gent","year":"2024","unstructured":"Gent DG, Saif M, Dobson R, Wright DJ. Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024;6(4):475\u201395. https:\/\/doi.org\/10.1016\/j.jaccao.2024.06.004.","journal-title":"JACC CardioOncol"},{"issue":"21","key":"2397_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70329","volume":"13","author":"C Dai","year":"2024","unstructured":"Dai C, Lin W, Liu F, Chen X, Chen Y, Jiang Y, et al. Induction chemotherapy-related covert cardiac remodeling in pre-autologous hematopoietic stem cell transplantation for multiple myeloma: a retrospective observational study. Cancer Med. 2024;13(21):e70329. https:\/\/doi.org\/10.1002\/cam4.70329.","journal-title":"Cancer Med"},{"issue":"1","key":"2397_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamacardio.2023.4105","volume":"9","author":"JW Rhee","year":"2024","unstructured":"Rhee JW, Pillai R, He T, Bosworth A, Chen S, Atencio L, et al. Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant. JAMA Cardiol. 2024;9(1):16\u201324. https:\/\/doi.org\/10.1001\/jamacardio.2023.4105.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2397_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41409-020-01008-9","volume":"56","author":"A Williams","year":"2021","unstructured":"Williams A, Baruah D, Patel J, Szabo A, Chhabra S, Dhakal B, et al. Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(1):225\u201331. https:\/\/doi.org\/10.1038\/s41409-020-01008-9.","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2397_CR38","doi-asserted-by":"publisher","first-page":"e021686","DOI":"10.1161\/jaha.121.021686","volume":"10","author":"E Belzile-Dugas","year":"2021","unstructured":"Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc. 2021;10(18):e021686. https:\/\/doi.org\/10.1161\/jaha.121.021686.","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"2397_CR39","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/heartjnl-2020-318748","volume":"107","author":"M Fontes Oliveira","year":"2021","unstructured":"Fontes Oliveira M, Naaktgeboren WR, Hua A, Ghosh AK, Oakervee H, Hallam S, et al. Optimising cardiovascular care of patients with multiple myeloma. Heart. 2021;107(22):1774\u201382. https:\/\/doi.org\/10.1136\/heartjnl-2020-318748.","journal-title":"Heart"},{"issue":"12","key":"2397_CR40","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ejhf.1292","volume":"20","author":"N Pareek","year":"2018","unstructured":"Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018;20(12):1721\u201331. https:\/\/doi.org\/10.1002\/ejhf.1292.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2397_CR41","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s11357-025-01719-1","volume":"48","author":"Z Ungvari","year":"2026","unstructured":"Ungvari Z, Fekete M, Buda A, Lehoczki A, Munk\u00e1csy G, Scaffidi P, et al. Quantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis. Geroscience. 2026;48(1):1173\u201387. https:\/\/doi.org\/10.1007\/s11357-025-01719-1.","journal-title":"Geroscience"},{"key":"2397_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4087","volume":"371","author":"TP Hanna","year":"2020","unstructured":"Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. https:\/\/doi.org\/10.1136\/bmj.m4087.","journal-title":"BMJ"},{"issue":"5","key":"2397_CR43","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/ehf2.12840","volume":"7","author":"WT Chang","year":"2020","unstructured":"Chang WT, Feng YH, Kuo YH, Chen WY, Wu HC, Huang CT, et al. The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan. ESC Heart Fail. 2020;7(5):2135\u20139. https:\/\/doi.org\/10.1002\/ehf2.12840.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"2397_CR44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40959-023-00167-0","volume":"9","author":"Y Liu","year":"2023","unstructured":"Liu Y. A novel cardio-oncology service line model in optimizing care access, quality and equity for large, multi-hospital health systems. Cardiooncology. 2023;9(1):16. https:\/\/doi.org\/10.1186\/s40959-023-00167-0.","journal-title":"Cardiooncology"},{"key":"2397_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s44156-026-00115-5","author":"J Lushington","year":"2026","unstructured":"Lushington J, Kandala A, Bingcang J, Ferreira A, Byrne A, Sirker A, et al. Echocardiography in cardio-oncology: optimising service delivery. Echo Res Pract. 2026. https:\/\/doi.org\/10.1186\/s44156-026-00115-5.","journal-title":"Echo Res Pract"},{"issue":"41","key":"2397_CR46","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"issue":"5","key":"2397_CR47","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaccao.2024.07.017","volume":"6","author":"Z Raisi-Estabragh","year":"2024","unstructured":"Raisi-Estabragh Z, Murphy AC, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds KL, et al. Cardiovascular considerations before cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations. JACC CardioOncol. 2024;6(5):631\u201354. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.017.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2397_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00849-z","volume":"13","author":"J El-Cheikh","year":"2023","unstructured":"El-Cheikh J, Moukalled N, Malard F, Bazarbachi A, Mohty M. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13(1):83. https:\/\/doi.org\/10.1038\/s41408-023-00849-z.","journal-title":"Blood Cancer J"},{"key":"2397_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142375","author":"A Colomba","year":"2025","unstructured":"Colomba A, Airale L, Lasagno A, Mingrone G, Astarita A, Vallelonga F, et al. The emerging role of left atrial strain in cardiovascular risk stratification for multiple myeloma patients undergoing carfilzomib therapy. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17142375.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2397_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-025-00358-x","volume":"11","author":"LB Leypoldt","year":"2025","unstructured":"Leypoldt LB, Guo L, Besemer B, H\u00e4nel M, Raab MS, Mann C, et al. Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial. Cardio-Oncology. 2025;11(1):63. https:\/\/doi.org\/10.1186\/s40959-025-00358-x.","journal-title":"Cardio-Oncology"},{"key":"2397_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041278","author":"M Cronin","year":"2023","unstructured":"Cronin M, Crowley A, Davey MG, Ryan P, Abdelshafy M, Elkoumy A, et al. Heart failure association-International cardio-oncology society risk score validation in HER2-positive breast cancer. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12041278.","journal-title":"J Clin Med"},{"issue":"3","key":"2397_CR52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","volume":"46","author":"B Rivero-Santana","year":"2024","unstructured":"Rivero-Santana B, Salda\u00f1a-Garc\u00eda J, Caro-Cod\u00f3n J, Zamora P, Moliner P, Mart\u00ednez Monzonis A, et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2024;46(3):273\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehae496.","journal-title":"Eur Heart J"},{"issue":"3","key":"2397_CR53","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ehf2.13897","volume":"9","author":"D Di Lisi","year":"2022","unstructured":"Di Lisi D, Madaudo C, Alagna G, Santoro M, Rossetto L, Siragusa S, et al. The New HFA\/ICOS Risk Assessment Tool to Identify Patients with Chronic Myeloid Leukaemia at High Risk of Cardiotoxicity. ESC Heart Fail. 2022;9(3):1914\u20139. https:\/\/doi.org\/10.1002\/ehf2.13897.","journal-title":"ESC Heart Fail"},{"key":"2397_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142353","author":"A Astarita","year":"2025","unstructured":"Astarita A, Mingrone G, Airale L, Colomba A, Catarinella C, Cesareo M, et al. Validation of the HFA-ICOS score for carfilzomib-induced cardiotoxicity in multiple myeloma: a real-life perspective study. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17142353.","journal-title":"Cancers (Basel)"},{"key":"2397_CR55","doi-asserted-by":"publisher","first-page":"1624680","DOI":"10.3389\/fonc.2025.1624680","volume":"15","author":"D Qiao","year":"2025","unstructured":"Qiao D, Ding HB, Zhu CH, Chen RA, Nie L. Machine learning-based nomogram predicts heart failure risk in elderly relapsed\/refractory multiple myeloma patients receiving carfilzomib-based therapy. Front Oncol. 2025;15:1624680. https:\/\/doi.org\/10.3389\/fonc.2025.1624680.","journal-title":"Front Oncol"},{"key":"2397_CR56","doi-asserted-by":"publisher","first-page":"e63964","DOI":"10.2196\/63964","volume":"11","author":"H Mushcab","year":"2025","unstructured":"Mushcab H, Al Ramis M, AlRujaib A, Eskandarani R, Sunbul T, AlOtaibi A, et al. Application of Artificial Intelligence in Cardio-Oncology Imaging for Cancer Therapy-Related Cardiovascular Toxicity: Systematic Review. JMIR Cancer. 2025;11:e63964. https:\/\/doi.org\/10.2196\/63964.","journal-title":"JMIR Cancer"},{"issue":"1","key":"2397_CR57","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41467-024-45733-x","volume":"15","author":"R Yagi","year":"2024","unstructured":"Yagi R, Goto S, Himeno Y, Katsumata Y, Hashimoto M, MacRae CA, et al. Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms. Nat Commun. 2024;15(1):2536. https:\/\/doi.org\/10.1038\/s41467-024-45733-x.","journal-title":"Nat Commun"},{"issue":"1","key":"2397_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/circoutcomes.124.011504","volume":"18","author":"EK Oikonomou","year":"2025","unstructured":"Oikonomou EK, Sangha V, Dhingra LS, Aminorroaya A, Coppi A, Krumholz HM, et al. Artificial intelligence-enhanced risk stratification of cancer therapeutics-related cardiac dysfunction using electrocardiographic images. Circ Cardiovasc Qual Outcomes. 2025;18(1):e011504. https:\/\/doi.org\/10.1161\/circoutcomes.124.011504.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2397_CR59","doi-asserted-by":"publisher","first-page":"1212983","DOI":"10.3389\/fcvm.2023.1212983","volume":"10","author":"P Morfino","year":"2023","unstructured":"Morfino P, Aimo A, Castiglione V, Chianca M, Vergaro G, Cipolla CM, et al. Cardiovascular toxicity from therapies for light chain amyloidosis. Front Cardiovasc Med. 2023;10:1212983. https:\/\/doi.org\/10.3389\/fcvm.2023.1212983.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2397_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40959-025-00435-1","volume":"12","author":"G Novo","year":"2026","unstructured":"Novo G, Stabile F, Di Lisi D, Madaudo C, Jaramillo S, Damiani F, et al. The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis. Cardiooncology. 2026;12(1):32. https:\/\/doi.org\/10.1186\/s40959-025-00435-1.","journal-title":"Cardiooncology"},{"issue":"1","key":"2397_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. 2020;324(1):79\u201389. https:\/\/doi.org\/10.1001\/jama.2020.5493.","journal-title":"JAMA"},{"issue":"8","key":"2397_CR62","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","volume":"11","author":"A Staron","year":"2021","unstructured":"Staron A, Zheng L, Doros G, Connors LH, Mendelson LM, Joshi T, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139. https:\/\/doi.org\/10.1038\/s41408-021-00529-w.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2397_CR63","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Sch\u00f6nland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38. https:\/\/doi.org\/10.1038\/s41572-018-0034-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"2397_CR64","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072.","journal-title":"Eur Heart J"},{"key":"2397_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70472","author":"M Garg","year":"2026","unstructured":"Garg M, Choudhuri S, Parrish C, Hawkins S, Lachmann H, Clayton L, et al. Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline. Br J Haematol. 2026. https:\/\/doi.org\/10.1111\/bjh.70472.","journal-title":"Br J Haematol"},{"issue":"4","key":"2397_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/jco-25-02558","volume":"44","author":"J Khwaja","year":"2026","unstructured":"Khwaja J, Kirkwood AA, Milani P, Yohannan B, Theodorakakou F, Weverling F, et al. New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System. J Clin Oncol. 2026;44(4):311\u201320. https:\/\/doi.org\/10.1200\/jco-25-02558.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2397_CR67","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420\u20137. https:\/\/doi.org\/10.1182\/blood-2012-12-473066.","journal-title":"Blood"},{"issue":"8","key":"2397_CR68","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jcmg.2021.01.016","volume":"14","author":"PR Huntjens","year":"2021","unstructured":"Huntjens PR, Zhang KW, Soyama Y, Karmpalioti M, Lenihan DJ, Gorcsan J 3rd. Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis. JACC Cardiovasc Imaging. 2021;14(8):1508\u201319. https:\/\/doi.org\/10.1016\/j.jcmg.2021.01.016.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"2397_CR69","doi-asserted-by":"publisher","first-page":"oead040","DOI":"10.1093\/ehjopen\/oead040","volume":"3","author":"P Geenty","year":"2023","unstructured":"Geenty P, Sivapathan S, Stefani LD, Zada M, Boyd A, Richards D, et al. A novel echocardiographic risk score for light-chain amyloidosis. Eur Heart J Open. 2023;3(3):oead040. https:\/\/doi.org\/10.1093\/ehjopen\/oead040.","journal-title":"Eur Heart J Open"},{"issue":"1","key":"2397_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-44912-x","volume":"9","author":"UA Tahir","year":"2019","unstructured":"Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep. 2019;9(1):8552. https:\/\/doi.org\/10.1038\/s41598-019-44912-x.","journal-title":"Sci Rep"},{"issue":"16","key":"2397_CR71","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/circulationaha.115.016567","volume":"132","author":"M Fontana","year":"2015","unstructured":"Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570\u20139. https:\/\/doi.org\/10.1161\/circulationaha.115.016567.","journal-title":"Circulation"},{"issue":"6","key":"2397_CR72","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","volume":"13","author":"JA Pan","year":"2020","unstructured":"Pan JA, Kerwin MJ, Salerno M, Native T, Mapping. Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis. JACC Cardiovasc Imaging. 2020;13(6):1299\u2013310. https:\/\/doi.org\/10.1016\/j.jcmg.2020.03.010.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"2397_CR73","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3324\/haematol.2018.205336","volume":"104","author":"T Dittrich","year":"2019","unstructured":"Dittrich T, Benner A, Kimmich C, Siepen FAD, Veelken K, Kristen AV, et al. Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica. 2019;104(7):1451\u20139. https:\/\/doi.org\/10.3324\/haematol.2018.205336.","journal-title":"Haematologica"},{"issue":"6","key":"2397_CR74","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.echo.2010.03.027","volume":"23","author":"D Bellavia","year":"2010","unstructured":"Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C, et al. Independent predictors of survival in primary systemic (AL) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr. 2010;23(6):643\u201352. https:\/\/doi.org\/10.1016\/j.echo.2010.03.027.","journal-title":"J Am Soc Echocardiogr"},{"issue":"20","key":"2397_CR75","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/heartjnl-2021-320703","volume":"108","author":"OC Cohen","year":"2022","unstructured":"Cohen OC, Sathyanath A, Petrie A, Ravichandran S, Law S, Manwani R, et al. Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis. Heart. 2022;108(20):1616\u201322. https:\/\/doi.org\/10.1136\/heartjnl-2021-320703.","journal-title":"Heart"},{"key":"2397_CR76","doi-asserted-by":"publisher","first-page":"132468","DOI":"10.1016\/j.ijcard.2024.132468","volume":"417","author":"J Lopez","year":"2024","unstructured":"Lopez J, Duarte G, Mark JD, Vergara Sanchez C, De Camps Martinez ER, Black AL, et al. Impact of cardiac conduction disease in patients with cardiac amyloidosis: A national retrospective cohort study. Int J Cardiol. 2024;417:132468. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132468.","journal-title":"Int J Cardiol"},{"issue":"17","key":"2397_CR77","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2400712.","journal-title":"N Engl J Med"},{"issue":"1","key":"2397_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","volume":"7","author":"A Blaes","year":"2025","unstructured":"Blaes A, Nohria A, Armenian S, Bergom C, Thavendiranathan P, Barac A, et al. Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. JACC CardioOncol. 2025;7(1):1\u201319. https:\/\/doi.org\/10.1016\/j.jaccao.2024.06.006.","journal-title":"JACC CardioOncol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02397-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:03:08Z","timestamp":1785783788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02397-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2397"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02397-x","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"25 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No animal or human subjects by the authors were used in this study.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"75"}}